Skip to main content
. 2022 Sep 6;19:218. doi: 10.1186/s12974-022-02582-z

Table 2.

Main results of the Mendelian randomization analysis

Outcome nSNPs Method OR (95% CI) P value PFDR
Neurodegenerative disease
 Alzheimer’s disease 15 IVW 1.064 (1.012 to 1.119) 0.014 0.056
 Parkinson’s disease 17 IVW 1.027 (0.966 to 1.093) 0.395 0.903
 Amyotrophic lateral sclerosis 20 IVW 1.038 (0.996 to 1.080) 0.075 0.240
Multiple sclerosis 11 IVW 1.008 (0.941 to 1.081) 0.811 0.927
Epilepsy
 Epilepsy 7 IVW 1.044 (1.016 to 1.072) 0.002 0.032
  Generalized epilepsy 6 IVW 1.059 (1.011 to 1.109) 0.013 0.069
  Focal epilepsy 6 IVW 1.055 (1.015 to 1.097) 0.007 0.056
Cerebrovascular diseases
 Ischemic stroke 17 IVW 1.012 (0.981 to 1.044) 0.462 0.739
  Large-artery atherosclerosis 17 IVW 1.011 (0.934 to 1.094) 0.795 0.978
  Small-vessel 16 IVW 0.978 (0.885 to 1.081) 0.662 0.883
  Cardioembolic 17 IVW 0.981 (0.915 to 1.051) 0.587 0.854
 Nontraumatic intracranial hemorrhage 13 IVW 1.064 (0.975 to 1.162) 0.165 0.440
 Subarachnoid hemorrhage 13 IVW 1.057 (0.931 to 1.200) 0.396 0.792
Migraine
 Migraine with aura 17 IVW 1.006 (0.935 to 1.082) 0.879 0.938
 Migraine without aura, drug-induced 17 IVW 0.888 (0.650 to 1.213) 0.454 0.807
 Migraine without aura and triptan purchases 17 IVW 1.003 (0.928 to 1.084) 0.936 0.936

Bold symbol indicated statistically significances (P < 0.05)

CI: confidence interval; FDR: false discovery rate; IVW: inverse-variance weighted; nSNPs: number of single-nucleotide polymorphisms; OR: odds ratio